Medicine Supply Notification: NovoRapid® (insulin aspart) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens
Department of Health and Social Care (DHSC) has issued a medicine supply notification for NovoRapid® (insulin aspart) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens
MSN/2024/103
Tier 2 – medium impact
Date of issue: 16th October 2024
TO NOTE: This is the first of three MSNs covering discontinuations with Novo Nordisk insulin products (NovoRapid® FlexTouch®, Insulatard® Penfill® and all Levemir® presentations). The remaining MSNs will be issued shortly. It should be noted that where alternative insulin products have been recommended consideration has been made both to these product discontinuations and the wider supply availability of insulin.
- NovoRapid® (insulin aspart) FlexTouch® 100units/ml solution for injection 3ml pre-filled pens are being discontinued; stock is anticipated to be exhausted by March 2025.
- NovoRapid® (insulin aspart) FlexPen® 100 units/ml solution for injection 3ml pre-filled pens remain available and can support a full increase in demand.
- NovoRapid® (insulin aspart) Penfill® 100 units/ml solution for injection 3ml cartridges remain available and can support a full increase in demand.
- Insulin aspart biosimilar, Trurapi® (100units/ml solution for injection in 3ml pre-filled SoloStar® pens and 3ml cartridges) remain available and can support a full increase in demand.
A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.
DHSC and NHS England have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.
The Tool also details any changes to resupply dates and updates to the entries.
To access the Tool you will need an NHS email address. Once set up and logged in, you will be able to access it online.
New shortages not listed on the SPS website, can be reported using our shortage reporting tool.
